(Q65374781)
Statements
A Phase 2a, Randomized, Double-blind, Sponsor Unblinded, Placebo-controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Subjects With Active Ulcerative Colitis (English)
0 references
March 2011
0 references
April 2013
0 references
84
0 references
18 year
0 references
65 year
0 references